CN107467569B - 一种增强人体免疫力的香菇复方制剂及其制备方法 - Google Patents
一种增强人体免疫力的香菇复方制剂及其制备方法 Download PDFInfo
- Publication number
- CN107467569B CN107467569B CN201710711140.3A CN201710711140A CN107467569B CN 107467569 B CN107467569 B CN 107467569B CN 201710711140 A CN201710711140 A CN 201710711140A CN 107467569 B CN107467569 B CN 107467569B
- Authority
- CN
- China
- Prior art keywords
- maca
- mushroom
- preparation
- drying
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 64
- 235000001674 Agaricus brunnescens Nutrition 0.000 title claims abstract description 59
- 150000001875 compounds Chemical class 0.000 title claims abstract description 47
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 30
- 230000036039 immunity Effects 0.000 title claims abstract description 29
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 111
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 111
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 111
- 240000000599 Lentinula edodes Species 0.000 claims abstract description 56
- 239000000284 extract Substances 0.000 claims abstract description 50
- 240000007651 Rubus glaucus Species 0.000 claims abstract description 26
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 17
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims description 41
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 37
- 238000002386 leaching Methods 0.000 claims description 14
- 238000000108 ultra-filtration Methods 0.000 claims description 14
- 229920001491 Lentinan Polymers 0.000 claims description 12
- 229940115286 lentinan Drugs 0.000 claims description 12
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 235000021013 raspberries Nutrition 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 8
- 101710130006 Beta-glucanase Proteins 0.000 claims description 6
- 235000019750 Crude protein Nutrition 0.000 claims description 6
- 101710166469 Endoglucanase Proteins 0.000 claims description 6
- 238000003672 processing method Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000011033 desalting Methods 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 3
- 229940044203 shiitake mushroom preparation Drugs 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 229920001542 oligosaccharide Polymers 0.000 abstract description 6
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 abstract description 3
- 230000003612 virological effect Effects 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000002155 anti-virotic effect Effects 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract description 2
- 230000001932 seasonal effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 15
- 235000013305 food Nutrition 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000005238 degreasing Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- LIEMBEWXEZJEEZ-INEUFUBQSA-N (2r,3r)-4-(6-aminopurin-9-yl)-2,3-dihydroxybutanoic acid Chemical compound NC1=NC=NC2=C1N=CN2C[C@@H](O)[C@@H](O)C(O)=O LIEMBEWXEZJEEZ-INEUFUBQSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LIEMBEWXEZJEEZ-UHFFFAOYSA-N D-threo-Leutysin Natural products NC1=NC=NC2=C1N=CN2CC(O)C(O)C(O)=O LIEMBEWXEZJEEZ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000801118 Lepidium Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001492261 Pleurotaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000005314 unsaturated fatty acid group Chemical group 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种增强人体免疫力的香菇复方制剂及其制备方法,所述香菇复方制剂由如下重量百分比的原料制成:香菇提取物45~70%,玛咖25~35%,树莓5~20%。本发明的香菇复方制剂,优化复配比例,组方之间具有高效的协同作用,有效成分含量高,功效显著,可以用于提高人体抗病毒、抗菌抗炎能力,增强人体抵抗疲劳、季节性感冒或病毒性感冒。所述复方制剂可以制成冲剂、片剂或口服液等多种剂型,对于体质较弱或亚健康人群可有效抵抗疲劳和各类相关疾病。同时,本发明中的香菇提取物含有香菇蛋白和香菇低聚糖,产率高,能够延伸香菇产业链,增加香菇附加值。
Description
技术领域
本发明属于保健品技术领域,更具体地,涉及一种增强人体免疫力的香菇复方制剂及其制备方法。
背景技术
香菇(Lentinus edodes),又名花菇、香蕈、香信、香菌、冬菇,为侧耳科植物香蕈的子实体。香菇是世界第二大食用菌,也是我国特产之一,在民间素有“山珍”之称。香菇味道鲜美,香气沁人,营养丰富。香菇的主要成分有香菇多糖、香菇嘌呤、核苷酸、维生素、三萜类化合物以及大量的蛋白质和氨基酸。干香菇含谷氨酸、丙氨酸、组氨酸、亮氨酸、苯丙氨酸、缬氨酸等多种氨基酸,具有较高的营养价值和药用价值。在我国,香菇主要以干品或鲜品销售,深加工相对较小,附加值小,直接影响着菇农的收入。
香菇的多糖提取物是目前研究较多的香菇深加工产品之一。香菇多糖有很明显的抗肿瘤活性,增强宿主对细菌、真菌、病毒和寄生虫感染的抵抗能力,增强自然杀伤细胞和细胞毒性T细胞活性等多种生物学和免疫学活性。然而,现在对于香菇其他重要营养成分的提取物研究还较少,例如对香菇蛋白和香菇低聚糖,它们没有得到很好的利用,是一种无形的资源浪费。
香菇低聚糖也是香菇的营养成分之一,同时也可通过香菇多糖的水解获得。低聚糖通常是通过糖苷键将2~4个单糖连接而成小聚体。香菇低聚糖可以用于改善人体内微生态环境,有利于双歧杆菌和其他有益菌的增殖;改善人体血脂代谢,增强人体免疫力,发热量很低,很少转化为脂肪,可在减肥食品、糖尿病患者食品或高血压病人食品等低能量食品中发挥作用。此外,鲜菇固形物中含粗蛋白19.9%,蛋白含量高。目前对于香菇蛋白的研究尚处于初级阶段,已有的实验结果表明香菇蛋白对体外培养的癌细胞u14有直接的细胞毒作用,明显抑制肿瘤细胞的生长,而且在体外能直接杀伤肿瘤细胞,并可诱导肿瘤细胞凋亡。菇蛋白能够激活机体的免疫系统,提高巨噬细胞、细胞因子的作用效果,来实现其抗肿瘤作用;香菇蛋白还能够有效抑制HIV-1逆转录酶的活性和白血病细胞的增殖。对于香菇蛋白的提取方法多直接采用碱法提取,但蛋白的得率以及活性均不十分理想,而且大量工业酒精的应用成为了香菇蛋白在食品领域应用的障碍。
玛咖(Lepedium meyenii Walp),原产于海拔4000米以上的秘鲁安第斯山区,属十字花科独行菜属。玛咖是一种药食两用植物,可食用部分为其根部。玛咖营养丰富,干根中含有10%以上的蛋白质,8.5%的纤维,其内含丰富的锌、钙、铁、钛、铷、钾、钠、铜、锰、镁、锶、磷、碘等矿物质,并含有维生素C、B1、B2、B6、A、E、B12、B5,脂肪多为不饱和脂肪酸,亚油酸和亚麻酸的含量达脂肪含量的53%以上,天然活性成分包含玛咖酰胺、玛咖稀、生物碱、多糖、芥子油苷及其分解产物异硫氰酸苄酯、甾醇、多酚类物质,是可以预防多种疾病的新资源食品。
虽然,现在市面上也出现了一些以香菇和玛咖为主要成分用于增强人体免疫力的保健产品,但是它们往往成分复杂,组方之间未进行优化配比,功效成分低,人体服用效果不明显,导致了不必要的浪费。
发明内容
针对上述现有技术中的不足,提供了一种增强人体免疫力的香菇复方制剂及其制备方法,所述复方制剂将香菇提取物、玛咖与树莓进行组合,富含多种人体所需的营养元素,使机体抗菌、抗炎、抗肿瘤和抗氧化等功能增强,效率高、天然无毒副作用。
本发明的上述目的是通过以下技术方案予以实现的。
一种增强人体免疫力的香菇复方制剂,由如下重量百分比的原料制成:香菇提取物45~70%,玛咖25~35%,树莓5~20%。
优选地,所述香菇复方制剂由如下重量百分比的原料制成:香菇提取物58%,玛咖30%,树莓12%。
优选地,所述香菇提取物的制备方法包括:
a.将香菇粉碎,浸提脱脂,干燥;
b.将脱脂后的干物料加水搅拌,再依次加入β-葡聚糖酶和碱性纤维素酶进行酶解;
c.将获得的酶解后溶液进行超滤,分别获得透过溶液和截留溶液;
d.将步骤c获得的透过溶液,经树脂脱盐,真空加热浓缩,喷雾干燥得香菇低聚糖;
e.将步骤c获得的截留溶液,调整pH至4.0~4.5,沉淀,离心,获得的粗蛋白经水洗、真空干燥得香菇蛋白。
更优选地,所述香菇提取物的制备方法包括:
a.前处理及脱脂:将香菇子实体于40~60℃烘干后,粉碎至40~80目,加入1:5~10质量比的食用级正己烷,温度30~60℃,提取时间1~3h,重复浸提1~3次,过滤,将提取后物料加热干燥,得脱脂后香菇子实体粉;
b.酶解:将步骤a得到的脱脂后香菇子实体粉,加1:10~20质量比的水,搅拌后加入脱脂物料重量0.3~1%的β-葡聚糖酶,调整温度至45~55℃,pH为4.5~6.0,持续酶解0.5~1h;然后调整至45~55℃,pH为10.0~11.0,加入0.9~3%的碱性纤维素酶,再持续酶解2~3h;
c.超滤:将b获得的酶解后溶液进行超滤,超滤膜截留分子量为10kD,超滤至透过溶液与截留溶液体积比为0.4:1~1:1为止,分别获得透过溶液和截留溶液;
d.将步骤c获得的透过溶液,经阴离子和阳离子树脂交换脱盐,真空加热浓缩至1/4~1/3体积,经喷雾干燥得香菇低聚糖;
e.将步骤c获得的截留溶液,调整pH至4.0~4.5,沉淀蛋白后,离心,获得的粗蛋白经水洗、真空干燥得到香菇蛋白。
优选地,所述玛咖包括玛咖根和玛咖叶,所述玛咖根和玛咖叶的重量份数比为5:2。将玛咖根与玛咖叶配合,玛咖叶中富含的维生素C和矿物质钙与玛卡根中含有的蛋白质,纤维,多种矿物质、维生素及天然活性成分混合。
优选地,所述玛咖根的处理方法包括:玛咖根粉碎至5~25目浸提,60~95%乙醇水溶液提取,在料液比1∶10~1∶15、65~80℃浸提2~4次,每次2~3h,玛咖酰胺总含量6~15%,浓缩干燥,玛咖根浸膏。
优选地,所述玛咖叶的处理方法包括:所述玛咖叶采用生长期茎叶,干燥,粉碎至80~120目。
优选地,所述树莓的处理方法包括:将树莓于50~65℃烘5~8h,粉碎至80~120目。
作为一种优选地实施方式,所述增强人体免疫力的香菇复方制剂的制备方法,包含如下步骤:
S1.按步骤a~e制备香菇提取物;
S2.将玛咖根粉碎至5~25目浸提,60~95%乙醇水提取,在料液比1∶10~1∶15、65~80℃浸提2~4次,每次2~3h,玛咖酰胺总含量6~15%,浓缩干燥,得到玛咖根浸膏;
S3.将树莓于50~65℃烘5~8h,粉碎至80~120目,再与步骤S1、S2获得的香菇提取物和玛咖根浸膏按照重量百分比均匀混合后,干燥,得到所述香菇复方制剂。
作为一种优选地实施方式,所述增强人体免疫力的香菇复方制剂的制备方法,包含如下步骤:
S1.制备香菇提取物;
S2.将玛咖按比例分为玛咖根和玛咖叶两部分,将玛咖根粉碎至5~25目浸提,60~95%乙醇水提取,在料液比1∶10~1∶15、65~80℃浸提2~4次,每次2~3h,玛咖酰胺总含量6~15%,浓缩干燥,得到玛咖根浸膏;
S3.将玛咖叶、树莓于50~65℃烘4~5h,粉碎至80~120目,混匀,再与步骤S1、S2获得的香菇提取物和玛咖根浸膏按重量百分比均匀混合后,干燥,得到所述香菇复方制剂。
与现有技术相比,本发明有益效果在于:提供了一种增强人体免疫力的香菇复方制剂,优化复配比例,组方之间具有高效的协同作用,有效成分含量高,功效显著,可以用于提高人体抗病毒、抗菌抗炎能力,增强人体抵抗疲劳、季节性感冒或病毒性感冒。所述复方制剂可以制成冲剂、片剂或口服液等多种剂型,对于体质较弱或亚健康人群可有效抵抗疲劳和各类相关疾病。同时,本发明中的香菇提取物含有香菇蛋白和香菇低聚糖,产率高,能够延伸香菇产业链,增加香菇附加值。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
以下以具体实施条件为例对本发明方法进行进一步说明。
实施例1
一种增强人体免疫力的香菇复方制剂,由如下重量百分比的原料制成:香菇提取物58%,玛咖30%,树莓12%。所述玛咖为玛咖根。
上述香菇复方制剂制备方法包括如下步骤:
S1.按步骤a~e制备香菇提取物;
a.前处理及脱脂:将香菇子实体于40℃烘干后,粉碎至80目,加入1:10质量比的食用级正己烷,温度30℃,提取时间3h,重复浸提3次,过滤,将提取后物料加热干燥,得脱脂后香菇子实体粉;
b.酶解:将步骤a得到的脱脂后香菇子实体粉,加1:20质量比的水,搅拌后加入脱脂物料重量0.3%的β-葡聚糖酶,调整温度至45℃,pH为4.5,持续酶解0.5h;然后调整至45℃,pH为11.0,加入0.9%的碱性纤维素酶,再持续酶解2h;
c.超滤:将b获得的酶解后溶液进行超滤,超滤膜截留分子量为10kD,超滤至透过溶液与截留溶液体积比为1:1为止,分别获得透过溶液和截留溶液;
d.将步骤c获得的透过溶液,经阴离子和阳离子树脂交换脱盐,真空加热浓缩至1/4体积,经喷雾干燥得香菇低聚糖;
e.将步骤c获得的截留溶液,调整pH至4.5,沉淀蛋白后,离心,获得的粗蛋白经水洗、真空干燥得到香菇蛋白;
S2.将玛咖根粉碎至25目浸提,95%乙醇水提取,在料液比1∶15、80℃浸提2次,每次2h,玛咖酰胺总含量6~15%,浓缩干燥,得到玛咖根浸膏;
S3.将树莓于65℃烘5h,粉碎至120目,再与步骤S1、S2获得的香菇提取物和玛咖根浸膏按照重量百分比均匀混合后,干燥,得到所述香菇复方制剂。
实施例2
一种增强人体免疫力的香菇复方制剂,由如下重量百分比的原料制成:香菇提取物70%,玛咖25%,树莓5%。
其他均与实施例1相同。
实施例3
一种增强人体免疫力的香菇复方制剂,由如下重量百分比的原料制成:香菇提取物45%,玛咖35%,树莓20%。
其他均与实施例1相同。
实施例4
一种增强人体免疫力的香菇复方制剂,配方与实施例1相同,不同之处在于,所述玛咖包括玛咖根和玛咖叶,所述玛咖根和玛咖叶的重量份数比为5:2。所述香菇复方制剂的制备方法中S2~S3与实施例1不同:
S2.将玛咖按比例分为玛咖根和玛咖叶两部分,将玛咖根粉碎至25目浸提,60%乙醇水提取,在料液比1∶10、80℃浸提2次,每次3h,玛咖酰胺总含量6~15%,浓缩干燥,得到玛咖根浸膏;
S3.将玛咖叶、树莓于65℃烘4h,粉碎至80目,混匀,再与步骤S1、S2获得的香菇提取物和玛咖根浸膏按重量百分比均匀混合后,干燥,得到所述香菇复方制剂。
实施例5
一种增强人体免疫力的香菇复方制剂,配方与实施例1相同,制备方法包括如下步骤:
S1.按步骤a~e制备香菇提取物;
a.前处理及脱脂:将香菇子实体于60℃烘干后,粉碎至40目,加入1:5质量比的食用级正己烷,温度60℃,提取时间1h,重复浸提1次,过滤,将提取后物料加热干燥,得脱脂后香菇子实体粉;
b.酶解:将步骤a得到的脱脂后香菇子实体粉,加1:10质量比的水,搅拌后加入脱脂物料重量1%的β-葡聚糖酶,调整温度至55℃,pH为6.0,持续酶解1h;然后调整至55℃,pH为10.0,加入3%的碱性纤维素酶,再持续酶解3h;
c.超滤:将b获得的酶解后溶液进行超滤,超滤膜截留分子量为10kD,超滤至透过溶液与截留溶液体积比为0.4:1为止,分别获得透过溶液和截留溶液;
d.将步骤c获得的透过溶液,经阴离子和阳离子树脂交换脱盐,真空加热浓缩至1/3体积,经喷雾干燥得香菇低聚糖;
e.将步骤c获得的截留溶液,调整pH至4.5,沉淀蛋白后,离心,获得的粗蛋白经水洗、真空干燥得到香菇蛋白;
S2.将玛咖根粉碎至5目浸提,60%乙醇水提取,在料液比1∶10、65℃浸提4次,每次3h,玛咖酰胺总含量6~15%,浓缩干燥,得到玛咖根浸膏;
S3.将树莓于50℃烘8h,粉碎至80目,再与步骤S1、S2获得的香菇提取物和玛咖根浸膏按照重量百分比均匀混合后,干燥,得到所述香菇复方制剂。
实施例6
一种增强人体免疫力的香菇复方制剂及其制备方法大体与实施例4相同,不同之处在于,所述香菇复方制剂的制备方法中S2~S3具体为:
S2.将玛咖按比例分为玛咖根和玛咖叶两部分,将玛咖根粉碎至5目浸提,95%乙醇水提取,在料液比1∶15、65℃浸提4次,每次2h,玛咖酰胺总含量6~15%,浓缩干燥,得到玛咖根浸膏;
S3.将玛咖叶、树莓于50℃烘5h,粉碎至120目,混匀,再与步骤S1、S2获得的香菇提取物和玛咖根浸膏按重量百分比均匀混合后,干燥,得到所述香菇复方制剂。
实施例7
一种增强人体免疫力的香菇复方制剂及其制备方法大体与实施例4相同,不同之处在于,所述玛咖根和玛咖叶的重量份数比为1:1。
实施例8
一种增强人体免疫力的香菇复方制剂,配方与实施例1相同,制备方法中香菇提取物的制备步骤a~b与实施例1不同,具体为:
a.前处理及脱脂:将香菇子实体于40℃烘干后,粉碎至80目,加入1:15质量比的食用级正己烷,温度30℃,提取时间3h,重复浸提3次,过滤,将提取后物料加热干燥,得脱脂后香菇子实体粉;
b.酶解:将步骤a得到的脱脂后香菇子实体粉,加1:20质量比的水,搅拌后加入脱脂物料重量3.5%的碱性纤维素酶,调整至45℃,pH为11.0,持续酶解2h;然后再调整温度至45℃,pH为4.5,加入脱脂物料重量1.5%的β-葡聚糖酶,再持续酶解0.5h。
对比例1
一种增强人体免疫力的香菇复方制剂,制备方法与实施例1相同,不同之处在于配方:香菇提取物25%,玛咖70%,树莓5%。
应用例
选取SPF级健康小鼠,体重20~25g,共100只,随机分成十组,在相同环境下培养;通过ConA诱导的小鼠脾淋巴细胞转化实验测定实施例1~8及对比例1增强免疫力的能力,给药剂量均为1.5g/60kg,同时设立溶剂对照组,灌胃蒸馏水,通过数据统计及计算,实验结果如表1所示。
表1不同香菇复方制剂对ConA诱导的小鼠脾淋巴细胞增殖能力的影响
与对照组相比,*P<0.05。
由实验结果可知,本发明香菇复方制剂对小鼠的脾淋巴细胞增殖具有促进作用,与对照组相比具有显著性差异;且本发明的香菇复方制剂在优化配比和制备方法的基础上,相比对比例能够显著增强机体免疫力。本发明的复方制剂可以制成冲剂、片剂、胶囊、口服液等多种剂型,对于体弱多病、亚健康人群等均具有良好疗效,应用前景广阔。
以上详细描述了本发明的实施,但是,本发明并不限于上述实施方式中的具体细节,在本发明的技术构思范围内,可以对本发明的技术方案进行多种简单变型,这些简单变型均属于本发明的保护范围。
Claims (7)
1.一种增强人体免疫力的香菇复方制剂,其特征在于,由如下重量百分比的原料制成:香菇提取物45~70%,玛咖25~35%,树莓5~20%;所述玛咖包括玛咖根和玛咖叶,所述玛咖根和玛咖叶的重量份数比为5:2;所述香菇提取物的制备方法包括:
a.将香菇粉碎,浸提脱脂,干燥;
b.将脱脂后的干物料加水搅拌,再依次加入β-葡聚糖酶和碱性纤维素酶进行酶解;
c.将获得的酶解后溶液进行超滤,分别获得透过溶液和截留溶液;
d.将步骤c获得的透过溶液,经树脂脱盐,真空加热浓缩,喷雾干燥得香菇低聚糖;
e.将步骤c获得的截留溶液,调整pH至4.0~4.5,沉淀,离心,获得的粗蛋白经水洗、真空干燥得香菇蛋白。
2.根据权利要求1所述的一种增强人体免疫力的香菇复方制剂,其特征在于,由如下重量百分比的原料制成:香菇提取物58%,玛咖30%,树莓12%。
3.根据权利要求1所述的一种增强人体免疫力的香菇复方制剂,其特征在于,所述玛咖根的处理方法包括:玛咖根粉碎至5~25目浸提,60~95%乙醇水溶液提取,在料液比1∶10~1∶15、65~80℃浸提2~4次,每次2~3h,玛咖酰胺总含量6~15%,浓缩干燥,玛咖根浸膏。
4.根据权利要求1所述的一种增强人体免疫力的香菇复方制剂,其特征在于,所述玛咖叶的处理方法包括:所述玛咖叶采用生长期茎叶,干燥,粉碎至80~120目。
5.根据权利要求 1所述的一种增强人体免疫力的香菇复方制剂,其特征在于,所述树莓的处理方法包括:将树莓于50~65℃烘5~8h,粉碎至80~120目。
6.权利要求1所述增强人体免疫力的香菇复方制剂,其特征在于,包含如下步骤:
S1.按步骤a~e制备香菇提取物;
S2.将玛咖根粉碎至5~25目浸提,60~95%乙醇水提取,在料液比1∶10~1∶15、65~80℃浸提2~4次,每次2~3h,玛咖酰胺总含量6~15%,浓缩干燥,得到玛咖根浸膏;
S3.将树莓于50~65℃烘5~8h,粉碎至80~120目,再与步骤S1、S2获得的香菇提取物和玛咖根浸膏按照重量百分比均匀混合后,干燥,得到所述香菇复方制剂。
7.权利要求1所述增强人体免疫力的香菇复方制剂,其特征在于,包含如下步骤:
S1.制备香菇提取物;
S2.将玛咖按比例分为玛咖根和玛咖叶两部分,将玛咖根粉碎至5~25目浸提,60~95%乙醇水提取,在料液比1∶10~1∶15、65~80℃浸提2~4次,每次2~3h,玛咖酰胺总含量6~15%,浓缩干燥,得到玛咖根浸膏;
S3.将玛咖叶、树莓于50~65℃烘4~5h,粉碎至80~120目,混匀,再与步骤S1、S2获得的香菇提取物和玛咖根浸膏按重量百分比均匀混合后,干燥,得到所述香菇复方制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710711140.3A CN107467569B (zh) | 2017-08-18 | 2017-08-18 | 一种增强人体免疫力的香菇复方制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710711140.3A CN107467569B (zh) | 2017-08-18 | 2017-08-18 | 一种增强人体免疫力的香菇复方制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107467569A CN107467569A (zh) | 2017-12-15 |
CN107467569B true CN107467569B (zh) | 2020-08-11 |
Family
ID=60600754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710711140.3A Active CN107467569B (zh) | 2017-08-18 | 2017-08-18 | 一种增强人体免疫力的香菇复方制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107467569B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108265092B (zh) * | 2017-12-26 | 2021-07-27 | 天津大学 | 一种具有优良抗氧化活性的香菇寡糖及制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105795460A (zh) * | 2016-03-23 | 2016-07-27 | 云南还原医学生物科技有限公司 | 一种可提高人体免疫力的玛咖与野生菌组合物 |
-
2017
- 2017-08-18 CN CN201710711140.3A patent/CN107467569B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105795460A (zh) * | 2016-03-23 | 2016-07-27 | 云南还原医学生物科技有限公司 | 一种可提高人体免疫力的玛咖与野生菌组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN107467569A (zh) | 2017-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004276123B2 (en) | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract | |
CN102273680B (zh) | 一种金针菇多糖复合饮料及其制备方法 | |
CN102924622B (zh) | 向日葵多糖及其制备方法 | |
CN106912953A (zh) | 虫草多糖复合物及其应用 | |
KR101487542B1 (ko) | 면역 증강용 인삼 다당체 제조방법 및 이 제조방법에 의해 제조된 면역 증강용 인삼 다당체 | |
CN104054610B (zh) | 一种鳗鱼的养殖方法 | |
CN101991165B (zh) | 红薯叶-紫苏叶复合饮料及其制备方法 | |
CN107638560A (zh) | 一种食用菌活性肽的制备方法 | |
CN102960789A (zh) | 板蓝根红枣浓浆产品 | |
CN112535239B (zh) | 一种用于禽畜日常保健促生长的复方中草药饲料添加剂及其制备及应用 | |
CN104068302A (zh) | 一种浒苔多糖口服液及其制备方法 | |
Prasad et al. | Promising medicinal role of Moringa oleifera: a review | |
CN101575359A (zh) | 一种水溶性螺旋藻藻胆蛋白的提取方法 | |
CN102994305A (zh) | 用蛹虫草、茧提取物制备保健食(疗)品之营养露酒的方法 | |
JP6534443B2 (ja) | 竹発酵抽出物の製造方法及び免疫賦活用食品組成物又は免疫賦活剤の製造方法 | |
CN108210878A (zh) | 补肾生精的虫草雪莲多糖复合物 | |
CN103099248A (zh) | 一种制备牡蛎活性成份的方法 | |
CN103798751A (zh) | 一种松露营养片 | |
CN107467569B (zh) | 一种增强人体免疫力的香菇复方制剂及其制备方法 | |
CN105853491B (zh) | 一种具有增进生殖能力功能的组合物及以玛咖为原料制备该组合物的方法 | |
CN101870940B (zh) | 一种添加牡蛎活性物质的啤酒制备方法 | |
CN111803531A (zh) | 一种蒲公英叶水溶性粗提物的制备方法及其应用 | |
KR20180098888A (ko) | 땅콩새싹 추출물을 유효성분으로 포함하는 면역력 증강용 조성물 | |
CN105192820A (zh) | 一种降血脂蛹虫草多糖饮料及其制备方法 | |
CN102987501B (zh) | 用蛹虫草、茧提取物制备保健食(疗)品之营养(液)饮料及冲剂的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200602 Address after: 264006 No. 15 Guiyang Street, Yantai Economic and Technological Development Zone, Shandong Province Applicant after: YANTAI NEW ERA HEALTH INDUSTRY Co.,Ltd. Address before: 430075 B4, Wuhan Institute of biotechnology, 666 hi tech Avenue, East Lake Development Zone, Hubei, Wuhan, China Applicant before: WUHAN HUASHITE INDUSTRIAL BIOTECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |